-
Nektar Therapeutics Secures $150M From SFJ Pharma For New Study With BEMPEG/Pembrolizumab Combo In Head & Neck Cancer
Wednesday, February 17, 2021 - 10:25am | 361Read More...Nektar Therapeutics (NASDAQ: NKTR) announces a financing and co-development collaboration with privately-held SFJ Pharmaceuticals to develop Bempegaldesleukin (BEMPEG) CD122-preferential IL-2–pathway agonist. The collaboration between SFJ and Nektar will support a new...
